My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Viatris Inc. - Common Stock (NQ:VTRS)

15.77 -0.02 (-0.13%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Viatris Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Viatris Stock: Bear vs. Bull ↗

August 31, 2023

This is a case where both sides have compelling arguments.

Via The Motley Fool

Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris ↗

August 24, 2023

Via The Motley Fool

Where Will Viatris Be in 5 Years? ↗

August 18, 2023

Can this become a good growth business to invest in?

Via The Motley Fool

Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy? ↗

August 16, 2023

There are a few complicating factors that mean the generic form of the drug might not be a slam dunk.

Via The Motley Fool

2 Beaten-Down Dividend Stocks to Buy ↗

August 11, 2023

These two stocks look like bargains right now for income investors.

Via The Motley Fool

If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today ↗

August 11, 2023

Would you have been better off investing in the S&P 500?

Via The Motley Fool

Topics Stocks

Is Viatris Stock Good for Dividend Income? ↗

August 09, 2023

If you keep your expectations in check, it could be a great pick.

Via The Motley Fool

A Preview Of Viatris's Earnings ↗

August 04, 2023

Via Benzinga

Viatris Stock: Bull vs. Bear ↗

July 22, 2023

Viatris shares have declined in the double digits over the past few years.

Via The Motley Fool

Daily Stock Analysis: Viatris ↗

July 20, 2023

Viatris Inc’s most recent $0.12 quarterly dividend, paid June 16th to shareholders of record May 23rd, equates to $0.48 annually to throw a yield of 4.58%.

Via Talk Markets

Viatris Q2 Earnings Beat Estimates, Multiple Sclerosis Therapy Accepted For FDA Review ↗

August 07, 2023

Viatris Inc (NASDAQ: VTRS) reported Q2 FY23 sales of $3.91 billion, up 2% on a divestiture-adjusted operational basis, marginally higher the

Via Benzinga

Elanco Animal Health, Sovos Brands, Veritiv, Graham And Other Big Stocks Moving Higher On Monday ↗

August 07, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 300 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years ↗

August 04, 2023

If you're patient and consistent, it won't be too hard to build up a revenue stream.

Via The Motley Fool

1 Reason I Wouldn't Buy This High-Yielding Dividend Stock ↗

July 20, 2023

Unless you're only in it for the dividend, you might be disappointed with this stock.

Via The Motley Fool

Better Pharma Buy: Viatris vs. Pfizer ↗

July 19, 2023

Both stocks look cheap today.

Via The Motley Fool

Better High-Yield Dividend Stock: Altria or Viatris? ↗

July 15, 2023

Which of these top income stocks is the better buy right now?

Via The Motley Fool

A Look Into Healthcare Sector Value Stocks ↗

July 17, 2023

Via Benzinga

3 Reasons to Buy Viatris Stock, and 1 Reason to Sell ↗

July 14, 2023

This drugmaker could be a great stock to own over the coming years.

Via The Motley Fool

3 Healthcare Stocks With Healthy Dividends ↗

July 13, 2023

These pharmaceutical companies all combine relatively high dividends with safe payout ratios.

Via The Motley Fool

3 Beaten-Down Dividend Stocks That Look Like Bargains Right Now ↗

July 10, 2023

These stocks have fallen so far over the past six months that they look like bargains that income-seeking investors don't want to pass up.

Via The Motley Fool

3 Stocks to Snag for Less Than Book Value ↗

July 07, 2023

One of the financial ratios used when screening for hidden opportunities in stocks is price-to-book value. Here are three.

Via InvestorPlace

Why Dividend Stocks Should Be a Key Part of Your Retirement Plan ↗

July 07, 2023

You can collect the dividend income while keeping your original investment intact.

Via The Motley Fool

Wall Street Thinks Viatris Stock Will Rise 25% -- Could It Grow Even More? ↗

July 05, 2023

There are a few trends moving in the right direction, and they could easily add up.

Via The Motley Fool

Fresh Blood: 3 Stocks Ready to Rally Under New CEOs ↗

June 28, 2023

Here are three companies with new CEOs that could rally in the year ahead as new management shakes things up.

Via InvestorPlace

Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts ↗

June 26, 2023

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2023 ↗

June 23, 2023

Via Benzinga

Warren Buffett Owns These 5 High-Yield Dividend Stocks. Should You? ↗

June 18, 2023

Not all of these high-yield stocks are great picks for investors now, but several of them are.

Via The Motley Fool

These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys ↗

June 08, 2023

These stocks are both down 20% in the past year. Now could be the time to load up on them.

Via The Motley Fool

Looking for Passive Income at a Decent Price? Buy These 2 Stocks ↗

June 05, 2023

If you're willing to accept slower growth, there are great bargains awaiting.

Via The Motley Fool

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.